315 related articles for article (PubMed ID: 33733337)
1. Radiomics-based model using gadoxetic acid disodium-enhanced MR images: associations with recurrence-free survival of patients with hepatocellular carcinoma treated by surgical resection.
Zhang L; Hu J; Hou J; Jiang X; Guo L; Tian L
Abdom Radiol (NY); 2021 Aug; 46(8):3845-3854. PubMed ID: 33733337
[TBL] [Abstract][Full Text] [Related]
2. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation.
Shan QY; Hu HT; Feng ST; Peng ZP; Chen SL; Zhou Q; Li X; Xie XY; Lu MD; Wang W; Kuang M
Cancer Imaging; 2019 Feb; 19(1):11. PubMed ID: 30813956
[TBL] [Abstract][Full Text] [Related]
3. Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure.
Zhu WS; Shi SY; Yang ZH; Song C; Shen J
World J Gastroenterol; 2020 Mar; 26(11):1208-1220. PubMed ID: 32231424
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction.
Zhang Z; Jiang H; Chen J; Wei Y; Cao L; Ye Z; Li X; Ma L; Song B
Cancer Imaging; 2019 May; 19(1):22. PubMed ID: 31088553
[TBL] [Abstract][Full Text] [Related]
5. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
Wang W; Gu D; Wei J; Ding Y; Yang L; Zhu K; Luo R; Rao SX; Tian J; Zeng M
Eur Radiol; 2020 May; 30(5):3004-3014. PubMed ID: 32002645
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging.
Chen S; Feng S; Wei J; Liu F; Li B; Li X; Hou Y; Gu D; Tang M; Xiao H; Jia Y; Peng S; Tian J; Kuang M
Eur Radiol; 2019 Aug; 29(8):4177-4187. PubMed ID: 30666445
[TBL] [Abstract][Full Text] [Related]
7. MRI-Based Radiomics: Associations With the Recurrence-Free Survival of Patients With Hepatocellular Carcinoma Treated With Conventional Transcatheter Arterial Chemoembolization.
Song W; Yu X; Guo D; Liu H; Tang Z; Liu X; Zhou J; Zhang H; Liu Y; Liu X
J Magn Reson Imaging; 2020 Aug; 52(2):461-473. PubMed ID: 31675174
[TBL] [Abstract][Full Text] [Related]
8. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy.
Liu Q; Li J; Liu F; Yang W; Ding J; Chen W; Wei Y; Li B; Zheng L
Cancer Imaging; 2020 Nov; 20(1):82. PubMed ID: 33198809
[TBL] [Abstract][Full Text] [Related]
9. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.
Deng PZ; Zhao BG; Huang XH; Xu TF; Chen ZJ; Wei QF; Liu XY; Guo YQ; Yuan SG; Liao WJ
World J Gastroenterol; 2022 Aug; 28(31):4376-4389. PubMed ID: 36159012
[TBL] [Abstract][Full Text] [Related]
10. Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma.
Yu Y; Fan Y; Wang X; Zhu M; Hu M; Shi C; Hu C
Eur Radiol; 2022 Feb; 32(2):959-970. PubMed ID: 34480625
[TBL] [Abstract][Full Text] [Related]
11. Radiomics Model Based on Gadoxetic Acid Disodium-Enhanced MR Imaging to Predict Hepatocellular Carcinoma Recurrence After Curative Ablation.
Zhang L; Cai P; Hou J; Luo M; Li Y; Jiang X
Cancer Manag Res; 2021; 13():2785-2796. PubMed ID: 33790652
[TBL] [Abstract][Full Text] [Related]
12. Using pre-operative radiomics to predict microvascular invasion of hepatocellular carcinoma based on Gd-EOB-DTPA enhanced MRI.
Lu XY; Zhang JY; Zhang T; Zhang XQ; Lu J; Miao XF; Chen WB; Jiang JF; Ding D; Du S
BMC Med Imaging; 2022 Sep; 22(1):157. PubMed ID: 36057576
[TBL] [Abstract][Full Text] [Related]
13. Radiomics Analysis Based on Multiparametric MRI for Predicting Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy.
Zhao Y; Wu J; Zhang Q; Hua Z; Qi W; Wang N; Lin T; Sheng L; Cui D; Liu J; Song Q; Li X; Wu T; Guo Y; Cui J; Liu A
J Magn Reson Imaging; 2021 Apr; 53(4):1066-1079. PubMed ID: 33217114
[TBL] [Abstract][Full Text] [Related]
14. Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma.
Fan Y; Yu Y; Wang X; Hu M; Hu C
BMC Med Imaging; 2021 Jun; 21(1):100. PubMed ID: 34130644
[TBL] [Abstract][Full Text] [Related]
15. Radiomics analysis enables recurrence prediction for hepatocellular carcinoma after liver transplantation.
Guo D; Gu D; Wang H; Wei J; Wang Z; Hao X; Ji Q; Cao S; Song Z; Jiang J; Shen Z; Tian J; Zheng H
Eur J Radiol; 2019 Aug; 117():33-40. PubMed ID: 31307650
[TBL] [Abstract][Full Text] [Related]
16. Radiomics model based on contrast-enhanced computed tomography to predict early recurrence in patients with hepatocellular carcinoma after radical resection.
Li SQ; Su LL; Xu TF; Ren LY; Chen DB; Qin WY; Yan XZ; Fan JX; Chen HS; Liao WJ
World J Gastroenterol; 2023 Jul; 29(26):4186-4199. PubMed ID: 37475840
[TBL] [Abstract][Full Text] [Related]
17. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
[TBL] [Abstract][Full Text] [Related]
18. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram.
Yuan C; Wang Z; Gu D; Tian J; Zhao P; Wei J; Yang X; Hao X; Dong D; He N; Sun Y; Gao W; Feng J
Cancer Imaging; 2019 Apr; 19(1):21. PubMed ID: 31027510
[TBL] [Abstract][Full Text] [Related]
19. Computed tomography-based radiomics to predict early recurrence of hepatocellular carcinoma post-hepatectomy in patients background on cirrhosis.
Qian GX; Xu ZL; Li YH; Lu JL; Bu XY; Wei MT; Jia WD
World J Gastroenterol; 2024 Apr; 30(15):2128-2142. PubMed ID: 38681988
[TBL] [Abstract][Full Text] [Related]
20. Prediction of early recurrence of hepatocellular carcinoma after liver transplantation based on computed tomography radiomics nomogram.
Zhao JW; Shu X; Chen XX; Liu JX; Liu MQ; Ye J; Jiang HJ; Wang GS
Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):543-550. PubMed ID: 35705443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
